Sangui Biotech International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
May 15, 2024 at 02:54 pm IST
Share
Sangui Biotech International, Inc. reported earnings results for the third quarter and nine months ended March 31, 2024. For the third quarter, the company reported revenue was USD 0.039879 million compared to USD 0.018697 million a year ago. Net income was USD 0.018805 million compared to net loss of USD 0.038191 million a year ago.
For the nine months, revenue was USD 0.094755 million compared to USD 0.070353 million a year ago. Net loss was USD 0.012854 million compared to USD 0.117248 million a year ago.
Sangui Biotech International, Inc. focuses on the development of pharmaceutical, medical and cosmetic products. The Company develops its products through its German subsidiary, SanguiBioTech AG (Sangui GmbH). It is engaged in seeking to market and selling its products through partnerships with industry partners across the world. It focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. It focuses its development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. It offers external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin.
SANGUI BIOTECH INTERNATIONAL, INC. 
